This week, the annual meeting of the American Diabetes
Association should focus the spotlight on many companies
developing new drug treatments for diabetes (see last weekGÇÖs
biotech piece). Diabetes is a growing problem,
particularly in children, and costs this countryGÇÖs healthcare
system billions of dollars. Despite being effective, todayGÇÖs
treatment

The biotechs have experienced a nice run since March, a run fueled by anticipated positive news out of the recent ASCO meeting.-áWell, the meeting did not disappoint the medical profession

Starting today, the 6th Annual Meeting of the American Society of Gene Therapy begins in Washington, DC, and with it begins more potential trading opportunities. This meeting, although not as popular as ASCO, is sexier than ASCO by way of its content. It brings together scientists and companies to discuss the latest cutting-edge research in gene therapy for a variety of diseases. The presentations at this meeting are pushing the envelope in applying gene therapy to the treatment of disease.

The American Society of Clinical OncologyGÇÖs annual meeting began this past weekend, and so far the early winner appears to be Genentech (DNA), on many fronts.-á

Let the ASCO games begin. It looks like the ASCO floodgates have busted wide open, based on yesterdayGÇÖs biotechGÇÖs wild ride.-á The momentum all started last week with GenentechGÇÖs (DNA) release of-á positive phase III data on its new anti-angiogenesis drug.-á The instigator yesterday was ImClone (IMCLE), with a news release before the opening bell.-á The company stated it would receive a $6 million milestone payment from its European partner Merck KGaA related to the upcoming release of phase III

It is only four days before the biggest meeting of
cancer specialists in the worldGǪ..and anything can
happen. Last Monday, Genentech (DNA) could not keep its
secret locked up any longer. On Monday morning, the
company fired the first preemptive shot by releasing positive
survival data on its new anti-angiogenesis drug Avastin for
the treatment

Will yesterdayGÇÖs wild ride for Genentech end?-áYesterday, the company initiated a preemptive release of crucial phase III data on its developing anti-angiogenesis drug Avastin a week before the start of this yearGÇÖs ASCO meeting.-áIt was a thing of beauty and caught everyone off gu

The 39th annual gathering of the American Society of Clinical Oncology (ASCO) is only eleven days away (May 31 to June 3) and already Wall Street speculation is brewing on which company will the toast of the meeting.-áThe ASCO meeting is the largest of the year for cancer specialists to present

Genentech announced this morning before the bell that a Phase III trial testing their new drug Avastin with chemotherapy improved overall survival in previously untreated patients with metastatic colorectal cancer.-áThis is significant news.-áAvastin is a monoclonal antibody aimed at a

After trading hours yesterday, an FDA Advisory panel unanimously approved a novel approach to treating asthma, a disease that affects millions of people worldwide. Genentech (DNA), Novartis (NOV), and the small biotech